NCT00038259View on ClinicalTrials.gov

Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug Therapy

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Study Completion Date

May 31, 2006

Conditions

HIV Infections

Interventions

DRUG

Aldesleukin

Trial Locations (10)

90502

UCLA CARE Center CRS, Los Angeles

95814

UC Davis Medical Center, Sacramento

Univ. of California Davis Med. Ctr., ACTU, Sacramento

96816

Univ. of Hawaii at Manoa, Leahi Hosp., Honolulu

775550435

Univ. of Texas Medical Branch, ACTU, Galveston

94305-5107

Stanford CRS, Palo Alto

Santa Clara Valley Med. Ctr., San Jose

San Mateo County AIDS Program, San Mateo

33136-1013

Univ. of Miami AIDS CRS, Miami

Unknown

MetroHealth CRS, Cleveland

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00038259 - Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug Therapy | Biotech Hunter | Biotech Hunter